strategies-for-stabilizing-novel-antibody-formats
Novel antibody formats like bispecifics and ADCs revolutionize therapy but present unique stability challenges. The old playbook won't work for issues like aggregation or degradation. Discover key formulation strategies to bring your promising candidates to the clinic.
Menu
Stabilizing the Next Wave: Formulation Strategies for Novel Antibody Formats
FAQ
Current Situation
Typical Market Trends
Current Challenges and How They Are Solved
How Leukocare Can Support These Challenges
Value Provided to Customers
Stabilizing the Next Wave: Formulation Strategies for Novel Antibody Formats
The field of antibody therapeutics is moving beyond standard monoclonal antibodies (mAbs). We're now seeing a surge in novel formats like bispecific antibodies, antibody-drug conjugates (ADCs), and various engineered fragments.[1, 2] This evolution allows us to tackle diseases in new ways, but it also brings a fresh set of formulation challenges. The complex structures of these molecules mean the old playbook for stabilizing biologics doesn't always apply. For CMC and Drug Product Development leaders, navigating this new territory is key to moving promising candidates from the lab to the clinic.
Current Situation
The move toward more complex antibody formats is driven by the need for higher efficacy and new mechanisms of action.[3] Bispecific antibodies can engage two different targets, creating effects that a combination of two separate mAbs cannot.[1] ADCs deliver potent cytotoxic drugs directly to cancer cells, a targeted approach to therapy.[4] These designs are impressive, but their asymmetry, conjugated payloads, and engineered domains introduce unique stability risks. Issues like aggregation, chemical degradation, and particle formation can be more pronounced, demanding a more sophisticated formulation approach right from the start.
Typical Market Trends
The pipelines for these advanced biologics are growing rapidly. The global antibody therapeutics market is projected to grow significantly, reaching an estimated value of USD 301 billion by 2035, up from USD 144.7 billion in 2025.[5] Much of this growth is fueled by next-generation formats like bispecifics and ADCs.[2]
A parallel trend is the push for subcutaneous (SC) delivery.[6, 7] SC injection is more convenient for patients and reduces healthcare costs compared to intravenous (IV) infusion.[7] It requires high-concentration formulations, often exceeding 100 mg/mL, which introduces significant challenges.[10, 8]. High protein concentrations can lead to increased viscosity and a greater propensity for aggregation, complicating both manufacturing and administration.[10, 8]. This pressure is magnified by accelerated development timelines, which require teams to establish a robust, commercially viable formulation earlier than ever before.
Current Challenges and How They Are Solved
Successfully developing a novel antibody format hinges on overcoming a few key stability and manufacturing hurdles.
Physical Instability: Aggregation and Particle Formation
The unique structures of novel antibody formats often expose new hydrophobic regions or create charge imbalances that make them more likely to aggregate.[11, 4] For ADCs, the conjugation process itself can introduce impurities that seed aggregation.
How it's solved: The solution lies in careful excipient selection. Non-ionic surfactants and specific amino acids are screened to find the optimal combination that minimizes protein-protein interactions.[12, 13]. Advanced analytical methods are used to detect early signs of aggregation, allowing for quick adjustments to the formulation buffer and pH. The goal is to build a comprehensive understanding of the molecule's behavior under different stress conditions.
Chemical Degradation: Protecting Complex Structures
Novel formats can degrade in ways not typically seen with standard mAbs. Oxidation might occur at new hotspots in engineered domains, or the chemical linker in an ADC could prove unstable, leading to premature payload release.[4, 11]
How it's solved: Controlling the formulation's pH is fundamental. For specific risks like oxidation, antioxidants may be added. With ADCs, the stability of the linker is a central part of the design process, requiring a deep understanding of its chemistry to ensure the payload stays attached until it reaches the target cell.[4]
High Viscosity in High-Concentration Formulations
To make subcutaneous injection feasible, a large dose must fit into a small volume, often driving protein concentrations to very high levels.[14] This frequently results in high viscosity, making the product difficult to manufacture, filter, and inject.[15, 16].
How it's solved: Formulators screen for viscosity-reducing excipients. Amino acids like arginine have been shown to effectively lower viscosity in some high-concentration mAb solutions.[17] Early assessment of a molecule's viscosity behavior with predictive, low-volume tools helps identify potential challenges long before large quantities of material are produced.[18]
How Leukocare Can Support These Challenges
Addressing these formulation challenges requires more than just standard screening. It requires a strategic partnership focused on data-driven science and a deep understanding of specific modalities.
Our approach is built on creating a robust formulation strategy from the ground up. Instead of relying on templates, we use a smart formulation platform that combines predictive modeling with high-throughput experimental work.[19] This allows us to map out the formulation space efficiently, identifying optimal conditions with a minimal amount of your valuable material.
For a fast-track biotech with a novel molecule, this means we can help you get to a stable, regulatory-sound formulation faster. For a mid-sized team tackling a new modality for the first time, we act as a dedicated partner, bringing specialized knowledge on ADCs or viral vectors to support your internal experts. We focus on generating clear, defensible data that builds a strong CMC story for investors and regulatory bodies alike. Our work is designed to de-risk your development program by providing a formulation designed for success.
Value Provided to Customers
Working with a dedicated formulation partner brings tangible value, especially for teams navigating the pressures of modern drug development.
Speed and Confidence: Our data-driven methods accelerate the path to a viable formulation, giving you confidence as you move toward clinical trials and BLA submission.
Structure and Clarity: We deliver hands-on support that provides structure for your development program. The result is a robust data package ready for Ph I and tailored for discussions with regulatory agencies.
Targeted Expertise: For teams facing new or complex challenges, we offer reliable, data-driven expertise for overflow projects or niche problems. We deliver results without the internal politics.
Real Data, Not Templates: We guide your modality's development path with real data and tailored formulation design, helping you de-risk internal decisions.
A Seamless Partnership: For CDMOs, we act as a silent, seamless formulation team that is always loyal to your client relationship, delivering science-backed results without friction.
FAQ
1. How early should we start thinking about formulation for a novel antibody format?
The earlier, the better. Early-stage formulation and developability assessments can identify potential liabilities in a molecule before significant resources are committed. Addressing stability or viscosity issues during candidate selection can prevent costly delays and failures down the road.
2. Our molecule is very complex. How is your approach different from a standard CRO?
Our approach is centered on a partnership model, not a transactional one. We act as a strategic co-pilot, using predictive modeling and deep scientific understanding to design a focused, tailored development plan. We don't believe in generic screening. We aim to solve specific problems by understanding the fundamental behavior of your molecule, saving time, material, and resources.
3. We already have an internal formulation team. How would a collaboration work?
We are here to support your team, not replace it. We often function as an extension of an internal group, taking on specific challenges like a new modality, a difficult high-concentration formulation, or providing additional capacity during peak workloads. This allows your team to stay focused on its core projects while we tackle specialized problems.
4. What kind of data do you provide for regulatory filings?
We provide a comprehensive data package designed to support IND and BLA submissions.[20, 21]. This includes a detailed rationale for the chosen formulation, complete stability data under various stress conditions, summaries of the analytical methods used, and a clear narrative that tells the story of your drug product's development.
